Are you looking for ways to expand your knowledge on leading life sciences topics to help accelerate your digital transformation this year? To help, we’ve compiled a number of articles that lay out some of the most trending healthcare topics at the moment: hybrid engagement strategies, automation, and artificial intelligence activation.
McKinsey: "Ready for launch: Reshaping pharma's strategy in the next normal”
Discover how personalization and digitalization are leading the way for future success.
Accenture: "The "new" rules of healthcare provider engagement"
See the key findings from a survey among 720 HCPs revealing how pharma can gain time, trust, and influence with HCPs and their patients.
Gartner: "The 2021 Market Guide for Sales Enablement Platforms"
Explore what the best-performing companies are doing now to set their customer-facing teams up for success.
Ernst & Young: “Pulse of the Industry - Medical Technology Report”
Examine five key areas where MedTechs should focus on rethinking their business models to deliver care better in the future.
BCG: “The Rise of the Next Generation of Medtech ‘Milkmen’"
Discover how medtech companies are reaping the benefits of transforming their commercial model, making them more effective, enabling better outcomes, and delivering greater value in health care.
Bigtincan: "The Definitive Guide to the Most Important Sales Enablement Metrics"
Explore the metrics that drive measurable value - the guide covers the most important sales enablement, sales engagement, and sales training metrics used by revenue managers and commercial leaders in pharma and medtech - and beyond.
Impatient Health: “2022 Predictions”
What will disrupt pharma and how are our customers changing in 2022? Will Amazon acquire TEVA? Most of us are hopeful for a better year after an extremely challenging 2020/21. This is lazy thinking. If we want a better 2022, now is the time for us to seize it. Doing so requires digging in— and looking up. Listen to the webinar or read the report on what the future of Pharma holds according to pharma provocateur and thought-leader Paul Simms.
